We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+30.98%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$283M
AUM Growth
+$43.4M
Cap. Flow
-$12.2M
Cap. Flow %
-4.31%
Top 10 Hldgs %
64.14%
Holding
48
New
7
Increased
14
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$4.5M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$4.23M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$3.98M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.06M
5
INSM icon
Insmed
INSM
+$2.29M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$7.75M
2
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$6.92M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$5.07M
4
PRTA icon
Prothena Corp
PRTA
+$4.6M
5
HROW icon
Harrow
HROW
+$2.86M

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
2 Communication Services 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$397M
$3.21M 1.13%
+450,500
New +$2.06M
NDRM
27
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.72M 0.96%
70,000
-50,300
-42% -$1.85M
PETX
28
DELISTED
Aratana Therapeutics, Inc.
PETX
$2.57M 0.91%
420,000
+69,800
+20% +$442K
RNAC icon
29
Cartesian Therapeutics
RNAC
$302M
$1.73M 0.61%
+3,167
New +$1.68M
SYRS
30
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.72M 0.61%
11,657
+707
+6% +$133K
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.65M 0.58%
+28,400
New +$3.06M
ARQL
32
DELISTED
Arqule Inc
ARQL
$1.35M 0.48%
1,220,000
+250,000
+26% +$288K
QUOT
33
DELISTED
Quotient Technology Inc
QUOT
$542K 0.19%
+110,000
New +$1.52M
BLRX
34
BioLineRX
BLRX
$12.1M
$280K 0.1%
417
– –
HROW icon
35
Harrow
HROW
$1.44B
– –
-895,000
Closed -$2.86M
PDSB icon
36
PDS Biotechnology
PDSB
$12.2M
– –
-6,500
Closed -$1.33M
PRTA icon
37
Prothena Corp
PRTA
$467M
– –
-85,000
Closed -$4.6M
TNXP icon
38
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– -$1.6M
WVE icon
39
Wave Life Sciences
WVE
$1.02B
– –
-125,000
Closed -$2.33M
VIRX
40
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-10,857
Closed -$1.03M
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-40,000
Closed -$1.09M
ZSAN
42
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-1,750
Closed -$1.73M
ADMS
43
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-290,000
Closed -$5.07M
NEOS
44
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-50,000
Closed -$365K
TTPH
45
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-16,500
Closed -$2.35M
NVLN
46
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
– –
-750,000
Closed -$6.92M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opaleye Management held 48 positions worth $283M, up 18% from $239M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Opaleye Management withdrew a net $12.2M in Q3 2017, closing 13 positions and reducing 4 holdings. Its most notable exit was Novelion Therapeutics Inc. Common Shares, an estimated $6.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Communication Services.

Against the trend, Opaleye Management opened a new position in Cymabay Therapeutics worth $5.36M.

  • Opaleye Management's largest Q3 2017 buy was Cymabay Therapeutics: 665,000 shares worth $5.36M.
  • Opaleye Management added most to Eagle Pharmaceuticals, Inc. in Q3 2017, an estimated $4.23M increase.
  • Opaleye Management's biggest Q3 2017 reduction was Blueprint Medicines, cutting an estimated $7.75M.
  • Opaleye Management fully exited Novelion Therapeutics Inc. Common Shares in Q3 2017, selling an estimated $6.92M.
  • Opaleye Management's ten largest holdings make up 64% of its $283M portfolio in Q3 2017.
  • Opaleye Management opened 7 new positions and closed 13 in Q3 2017.
  • Opaleye Management's portfolio value rose 18% quarter-over-quarter to $283M.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.